AMPEL BioSolutions is a company specialising in precision and personalised medicine, which recently announced a breakthrough treatment method that could change how healthcare professionals treat patients suffering from autoimmune and infectious diseases, as well as cancer. The company has done so by unveiling a technology that will use RNA analytics and machine learning to characterise the patient’s genes and provide clinical decision support to the healthcare professional. By doing so, the healthcare professional who is treating the patient can understand the best possible treatment method on an individual basis.
The technology is quite new; it has only been a concept for the last few years, but is now being used to launch a portfolio of more than ten clinical tests within the next five years. The clinical tests are aiming to provide decision support for diseases that are currently impacting more than 50 million people in the US alone. Having the ability to really treat the patient, as opposed to the disease, is important. While understanding the disease is necessary, every patient is different, and it is time that their treatment options reflect that. This technology will help physicians do so, and as a result, patient care will improve significantly.
AMPEL intends its technology to detect early signs of disease and then group patients by the severity of their condition, so their treatment is more precise. Currently, AMPEL’s technology is assisting more than 15 pharmaceutical companies in drug development and clinical trials. AMPEL expects to bring two products to the market over the next few years: LuGENE, which is a blood test for lupus, and Dermagene , a skin biopsy test for psoriasis, atopic dermatitis, scleroderma and lupus.
AMPEL also has a pipeline of big data tools, used to analyse large and complex clinical datasets. These products together will be a significant step forward for implementing routine testing to monitor disease activity and provide decision support. Big data and genomics are important for the future of healthcare. These tools provide healthcare professionals with a plethora of information, more than if they look solely at the disease. Access to gene expression and clinical datasets will provide a closer look at the individual as well as the disease. This type of care will become more common in the future, and Ampel BioSolutions is headed in the right direction.
This technology has the power to completely transform the way healthcare professionals treat their patients, and in turn, has the power to improve the quality of life for patients suffering from diseases.